Compare · ACHV vs ORKA
ACHV vs ORKA
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.23B, about 8.0x ACHV ($649.8M).
- Over the past year, ACHV is up 141.1% and ORKA is up 507.3% - ORKA leads by 366.2 points.
- ORKA has been more active in the news (5 items in the past 4 weeks vs 4 for ACHV).
- ORKA has more recent analyst coverage (11 ratings vs 9 for ACHV).
PerformanceACHV+141.06%ORKA+507.29%
2025-07-15+0.00%2026-07-15
- Company
- Achieve Life Sciences Inc.
- Oruka Therapeutics Inc.
- Price
- $6.34+0.48%
- $86.66-0.81%
- Market cap
- $649.8M
- $5.23B
- 1M return
- +14.65%
- +23.92%
- 1Y return
- +141.06%
- +507.29%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 9
- 11
ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV
- Achieve Life Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Achieve Life Sciences Joins Russell 2000® Index
- Raymond James resumed coverage on Achieve Life Sciences with a new price target
- Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
- SEC Form DEF 14A filed by Achieve Life Sciences Inc.
- SEC Form 4 filed by Director Waldman Reid Alexander
- SEC Form 4 filed by Director Farrow Jeffrey S
- New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)
- New insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)